Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07002060 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 640
- Enrollment target
NCT07002060 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 640 participants.
The verdict
NCT07002060, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 640 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years. Study details include: * The study duration will be up to approximately 6 months. * One single dose of the study intervention (vYF or YF-VAX) will be administered subcutaneously at the 1st visit. * The visit(V) frequency will be Day(D) 01 (V01) and D29 (V02). Two telephone calls will be planned at D15 and Month(M)6. Number of Participants: A total of 640 participants are expected to be included in the study in a 3:1 ratio (vYF: YF-VAX): Group 1: vYF; N=480 Group 2: YF-VAX; N=160 Study Arms and Duration: Randomized, active control (YF-VAX). 6 months duration per participants. Eligible participants will be randomized in a 3:1 ratio to receive, subcutaneously, a single dose of vYF or YF-VAX vaccines on D01.
Interventions
- BIOLOGICAL Yellow fever vaccine (live)
- BIOLOGICAL YF vaccine (live)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2026-01-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07002060
The ClinicalTrials.gov registry entry for NCT07002060 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Yellow fever vaccine (live) is the first listed.
NCT07002060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07002060 about?
NCT07002060 is a clinical study titled "Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults". The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years. Study details include: * The study duration will be up to approximately 6 months. * One single dose of the study interve...
What is the current status of trial NCT07002060?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2025-05-22. Estimated completion is 2026-01-20.
What interventions are being tested in trial NCT07002060?
The interventions under investigation include: Yellow fever vaccine (live) (BIOLOGICAL), YF vaccine (live) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07002060?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.